Bumadizone calcium dihydrate microspheres compressed tablets for colon targeting: formulation, optimization and in vivo evaluation in rabbits

References

• Abdallah M, Yuichi T, Hirofumi T. (2009). pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur J Pharm Biopharm 72:1–8
   PubMed Web of Science ®Google Scholar
• Allena RT, Gowda DV, Teja R. (2012). Formulation and evaluation of pectin-HPMC mesalamine tablets coated with Eudragit L 100 for ulcerative colitis. Der Pharm Lett 4:1093–102
   Google Scholar
• Ali NW, Zaazaa HA, Abdelkawy M, Magdy MA. (2012). Simultaneous HPTLC and RP-HPLC methods for determination of bumadizone in the presence of its alkaline-induced degradation product. Biomed Chromatogr 26:1143–9
   PubMed Web of Science ®Google Scholar
• Amrutiya N, Bajaj A, Madan M. (2009). Development of microsponges for topical delivery of mupirocin. Mercury 10:402–9
   Google Scholar
• Arunachalam C, Asha S. (2010). Pectinolytic enzyme – a review of new studies. Adv Biotechnol 561:1–5
   Google Scholar
• Baykara T. (2003). Preparation and in vitro evaluation of modified release ketoprofen microsponges. Il Faramaco 58:101–6
   PubMedGoogle Scholar
• Cosnes J, Grower-Rousseau C, Seksik P, Cortot A. (2011). Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 140:1785–94
   PubMed Web of Science ®Google Scholar
• Costa P, Manuel J, Lobo S. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123–33
   PubMed Web of Science ®Google Scholar
• Cui N, Friend DR, Fedorak RN. (1994). A budesonide prodrug accelerates treatment of colitis in rats. Gut 35:1439–46
   PubMed Web of Science ®Google Scholar
• El-kamel AH, Abdelaziz AM, Fatani AJ, El-subbagh HI. (2008). Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment. Int J Pharm 358:248–55
   PubMed Web of Science ®Google Scholar
• El Gamal SS, Naggar VF, Sokar MS. (2013). Colon targeting of theophylline from enzyme-dependent release tablet formulations: in vitro evaluation. Am J Res Commun 1:116–33
   Google Scholar
• Hathaway CA, Appleyard CB, Percy WH, Williams JL. (2012). Experimental colitis increases blood-brain barrier permeability in rabbits experimental colitis increases blood-brain barrier permeability in rabbits. AJP Gastrointest Liver Physiol 276:1174–80
   Google Scholar
• Ivy Leaf. (2007). In British Pharmacopoeia, 1st edn. London: The Stationary Office, 111–12, 153
   Google Scholar
• Jain V, Jain D, Singh R. (2011). Factors effecting the morphology of Eudragit S-100 based microsponges bearing dicyclomine for colonic delivery. J Pharm Sci 100:1545–52
   PubMed Web of Science ®Google Scholar
• Jelvehgari M, Siahi-Shadbad MR, Azarmi S, et al. (2006). The microsponge delivery system of benzoyl peroxide: preparation, characterization and release studies. Int J Pharm 308:124–32
   PubMed Web of Science ®Google Scholar
• Jelvehgari M, Maghsoodi M. (2010). Development of theophylline floating microballoons using cellulose acetate butyrate and/or Eudragit RL 100 polymers with different permeability characteristics. Res Pharm Sci 5:29–39
   Google Scholar
• Jelvehgari M, Montazam SH. (2012). Comparison of microencapsulation by emulsion-solvent extraction/evaporation technique using derivatives cellulose and acrylate-methacrylate copolymer as carriers. Jundishapur J Nat Pharm Prod 7:144–52
   PubMedGoogle Scholar
• Jones BE. (1988). Pharmaceutics: the science of dosage form design. Edinburgh, Churchill Livingstone: Longman Group, 322
   Google Scholar
• Klein A, Eliakim R. (2010). Non-steroidal anti-inflammatory drugs and inflammatory bowel disease. Pharmaceuticals 3:1084–92
   Google Scholar
• Kotagale NR, Parkhe AP, Jumde AB, et al. (2011). Ranitidine hydrochloride-loaded ethyl cellulose and Eudragit RS 100 buoyant microspheres: effect of ph modifiers. Indian J Pharm Sci 73:626–33
   PubMed Web of Science ®Google Scholar
• Kucharzik T, Walsh SV, Chen J, et al. (2001). Short communication neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol 159:2001–9
   PubMed Web of Science ®Google Scholar
• Lakshmana Prabu S, Shirwaikar AA, Shirwaikar A, Kumar A. (2009). Formulation and evaluation of sustained release microspheres of rosin containing aceclofenac. ARS Pharmaceutica 50:51–62
   Google Scholar
• Meissner Y, Pellequer Y, Lamprechat A. (2006). Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int J Pharm 316:138–43
   PubMed Web of Science ®Google Scholar
• Millar AD, Rampton DS, Chander CL, et al. (1996). Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 39:407–15
   PubMed Web of Science ®Google Scholar
• Munkholm P. (2003). Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Alimentary Pharmacol Ther 18:1–5
   PubMed Web of Science ®Google Scholar
• Okafor UA, Okochi VI, Chinedu SN, Onygemeokerenta BM. (2010). Pectinolytic activity of wild-type filamentous fungi fermented on agro-wastes. Afr J Microbiol Res 4:2729–34
   Web of Science ®Google Scholar
• Oz HS, Ebersole JL. (2008). Application of prodrugs to inflammatory diseases of the gut. Molecules (Basel, Switzerland) 13:452–74
   PubMed Web of Science ®Google Scholar
• Patel NV, Patel JK, Shah SH, Patel JJ. (2010). Design, development and in vitro evaluation of mesalamine tablets containing pectin and chitosan for colon-specific drug delivery. Int J Res Pharm Sci 1:94–102
   Google Scholar
• Percy WH, Burton MB, Fallick F, Burakoff R. (1990). A comparison in vitro of human and rabbit distal colonic muscle responses to inflammatory mediators. Gastroenterology 99:1324–32
   PubMed Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. (2008). Dose translation from animal to human studies revisited. FASEB J 22:659–61
   PubMed Web of Science ®Google Scholar
• Rowe RC, Sheskey PJ, Owen SC. (2006). Handbook of Pharmaceutical Excipients. London, UK: Pharmaceutical Press
   Google Scholar
• Saboji JK, Gadve RB, Patil SM. (2012). Development of oral colon specific pH dependent microcapsules of NSAID drug naproxen. J Appl Pharm Sci 2:202–11
   Google Scholar
• Schroeder B, Stevens J. (2003). An automated SPE procedure and analysis for the determination of ibuprofen and ketoprofen in plasma. GILSON 1–6
   Google Scholar
• Singh BN. (2007). Modified-release solid formulations for colonic delivery. Recent Pat Drug Deliv Formul 1:53–63
   PubMedGoogle Scholar
• Singh PK, Kumar S, Sharan G, Paradesh U. (2012). Formulation, devlopment and evaluation of colon targeted dosage form of Ibuprofen. Int J Pharm Sci Res 3:268–78
   Google Scholar
• Sinha VR, Kumria R. (2003). Microbially triggered drug delivery to the colon. Eur J Pharm Sci 18:3–18
   PubMed Web of Science ®Google Scholar
• Soad AY, Ahmed HE, Ibrahim S, Ahmed HS. (2009). Optimization of budesonide compression-coated tablets for colonic delivery. AAPS PharmSciTech 10:147–57
   PubMed Web of Science ®Google Scholar
• Swetha A, Gopal RM, Venkata RK, et al. (2011). Formulation and in-vitro evaluation of etodolac entrapped in mircosponge based drug delivery system. Int J Pharm 1:73–80
   Google Scholar
• Turkoglu M, Ugurlu T. (2002). In vitro evaluation of pectin–HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery. Eur J Pharm Biopharm 531:65–73
   Google Scholar
• Vandamme T, Lenourry A. (2002). The use of polysaccharides to target drugs to the colon. Carbohydr Polym 48:219–31
   Web of Science ®Google Scholar
• Verma A, Tripathi A, Saraf SA, Saraf S. (2010). Fabrication and evaluation of sustained release microspheres of ketorolac tromethamine. Int J Pharm Pharm Sci 2:44–8
   Google Scholar